Phreesia (NYSE:PHR) PT Lowered to $22.00 at SVB Leerink

Phreesia (NYSE:PHRGet Rating) had its target price dropped by SVB Leerink from $29.00 to $22.00 in a report issued on Friday, Stock Target Advisor reports. The brokerage currently has a “market perform” rating on the stock. SVB Leerink’s target price points to a potential upside of 15.79% from the stock’s previous close.

A number of other equities analysts also recently commented on the company. Citigroup lowered their price objective on Phreesia from $54.00 to $36.00 and set a “neutral” rating for the company in a research report on Thursday, March 31st. Royal Bank of Canada lowered their price objective on Phreesia from $51.00 to $29.00 and set a “sector perform” rating for the company in a research report on Thursday, April 7th. JPMorgan Chase & Co. lowered their price objective on Phreesia from $51.00 to $42.00 in a research report on Thursday, March 31st. Canaccord Genuity Group lowered their price objective on Phreesia from $81.00 to $49.00 in a research report on Thursday, March 31st. Finally, Canaccord Genuity Group lowered their price target on Phreesia from $81.00 to $49.00 and set a “buy” rating for the company in a report on Thursday, March 31st. Four research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $49.59.

NYSE PHR opened at $19.00 on Friday. The company has a market cap of $973.56 million, a P/E ratio of -8.15 and a beta of 1.39. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.65 and a quick ratio of 5.65. The stock has a 50-day moving average of $23.04 and a two-hundred day moving average of $33.39. Phreesia has a 1-year low of $13.19 and a 1-year high of $76.10.

Phreesia (NYSE:PHRGet Rating) last released its earnings results on Thursday, June 2nd. The company reported ($0.99) earnings per share for the quarter, beating the consensus estimate of ($1.09) by $0.10. The company had revenue of $63.35 million during the quarter, compared to the consensus estimate of $62.24 million. Phreesia had a negative return on equity of 25.34% and a negative net margin of 55.41%. Phreesia’s revenue was up 31.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.24) EPS. On average, analysts anticipate that Phreesia will post -4.22 EPS for the current fiscal year.

In other Phreesia news, General Counsel Allison C. Hoffman sold 3,909 shares of the business’s stock in a transaction that occurred on Monday, May 9th. The stock was sold at an average price of $17.07, for a total value of $66,726.63. Following the completion of the sale, the general counsel now owns 115,099 shares in the company, valued at $1,964,739.93. The sale was disclosed in a document filed with the SEC, which is available through this link. 5.50% of the stock is currently owned by insiders.

Hedge funds have recently made changes to their positions in the stock. Exane Derivatives grew its holdings in Phreesia by 5,845.5% in the fourth quarter. Exane Derivatives now owns 654 shares of the company’s stock valued at $27,000 after purchasing an additional 643 shares during the last quarter. Clearstead Advisors LLC acquired a new stake in Phreesia in the third quarter valued at $29,000. Sageworth Trust Co of South Dakota acquired a new stake in Phreesia in the fourth quarter valued at $33,000. First Horizon Advisors Inc. grew its holdings in Phreesia by 573.7% in the fourth quarter. First Horizon Advisors Inc. now owns 923 shares of the company’s stock valued at $38,000 after purchasing an additional 786 shares during the last quarter. Finally, Advisor Group Holdings Inc. grew its holdings in Phreesia by 63.4% in the fourth quarter. Advisor Group Holdings Inc. now owns 1,319 shares of the company’s stock valued at $55,000 after purchasing an additional 512 shares during the last quarter. 94.29% of the stock is currently owned by hedge funds and other institutional investors.

About Phreesia (Get Rating)

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments.

Read More

Stock Target Advisor logo

Analyst Recommendations for Phreesia (NYSE:PHR)

Want More Great Investing Ideas?

Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.